Transfusion-Associated Circulatory Overload Best Eliminated With Lasix

Transfusion-associated Circulatory Overload Clinical Trial

Official title:

Pre-transfusion Furosemide in Patients at High Risk of Transfusion-associated Circulatory Overload - The Transfusion-Associated Circulatory Overload Best Eliminated With Lasix (TACO-BEL) Study: A Pilot Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02802696
• Other study ID #: 16-5032
• Status: Completed
• Phase: Early Phase 1
• First received: February 29, 2016
• Last updated: June 23, 2017
• Start date: June 2016
• Est. completion date: April 15, 2017

Study information

• Verified date: October 2016
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot double-blinded placebo-controlled randomized controlled trial (RCT) to evaluate the feasibility of conducting a multicenter, randomized, placebo-controlled trial to assess the efficacy of pre-transfusion furosemide in preventing transfusion-associated circulatory overload (TACO) in hemodynamically stable inpatients aged 65 years or older receiving a single unit red blood cell transfusion. Patients will be randomly allocated to receive either furosemide (20mg intravenous) or placebo (saline) within 60 minutes of starting a red blood cell (RBC) transfusion. Randomization will be stratified by centre and renal dysfunction (creatinine clearance ≥ 60 mL/min or < 60 mL/min). This is a blinded trial: patients, care-providers (physicians and nurses), data collectors, outcome adjudicators, and data analysts will not be aware of group allocation.

Description:

The investigators proposed this pilot study to assist us in determining the feasibility of conducting a definitive multicenter randomized trial across Canada.

Rationale:

The rationale for this study includes: (1) TACO is the leading cause of morbidity and mortality due to transfusion; (2) risk factors for TACO include older age, renal dysfunction and positive fluid balance; (3) furosemide is a diuretic commonly prescribed for fluid overload; (4) furosemide can decrease pulmonary artery pressures; and (5) clinical uncertainty as to the effect of furosemide in preventing TACO. The investigators will enroll 80 patients in this pilot study at two centers.

Hypothesis:

The investigators hypothesize that 80 patients can be enrolled in the trial within a 2-month period

Justification:

If pre-transfusion that furosemide decreases the rate of TACO with red blood cell transfusion, clinical practice worldwide would change. Over 800,000 patients in Canada receive a blood transfusion annually and many are at high risk for TACO and may benefit from this simple, low-cost intervention. This intervention could easily be generalizable worldwide. There are practical challenges related to patient recruitment, adherence to trial protocol and data collection, all of which the TACO-BEL Pilot Trial will seek to measure.

Objectives:

The primary outcome of this trial is to determine the feasibility of performing a large multi-centre, randomized, placebo-controlled trial with concealed allocation and blinded outcome assessment, adequately powered to determine a clinically significant effect of pre-transfusion furosemide on the incidence of transfusion-associated circulatory overload.

Primary outcome measure is the number of patients enrolled within a two-month period

Secondary feasibility outcome measures include:

1. Proportion of patients screened meeting eligibility criteria

2. Proportion of eligible patients consenting to participate

3. Proportion of consenting patients receiving the allocated treatment

4. Proportion of treated patients completing follow-up assessment

5. Proportion of patients in which blinding was maintained throughout study

Research Method:

Patients meeting inclusion criteria will be identified by reviewing transfusion orders received by the blood transfusion laboratory or by referral from ordering physicians; these patients will then be approached by study personnel to obtain pre-transfusion informed consent. Randomization will be performed by pharmacy at the time of drug preparation. The randomization code will be generated in random blocks of 4 to 6, stratified by center, and renal function at time of randomization (creatinine clearance < 60 and ≥ 60 mL/min) using a computer based randomization program.

Intervention:

Patients will be administered a bolus dose of 20mg furosemide (20mg/2mL) intravenously within 60 minutes prior to the start of the red blood cell transfusion. Patients randomized to placebo will be administered an equal volume of normal saline intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 15, 2017
• Est. primary completion date: March 17, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Age = 65 years.

• Receiving a single unit red blood cell transfusion

Exclusion Criteria:

• Active bleeding (active visible bleeding, required 2 or more RBC units in the preceding 24 hours, drop in Hb > 20 g/L in the preceding 24 hours);

• Hemodynamically unstable (systolic blood pressure < 90 mmHg or on inotropes);

• Anticipated major surgical procedure within 24 hours of enrolment;

• Presence of hyponatremia (Na < 130 mmol/L);

• Presence of hypokalemia (K < 3.5 mmol/L);

• Dialysis or creatinine clearance < 30 mL/min;

• Order for platelet or plasma transfusion at same time;

• Allergy to furosemide;

• Risk of withholding furosemide felt by attending physician to place patient at excessive risk of harm;

• Previously enrolled in the study;

• Plan for discharge on the day of randomization;

• Unable to provide informed consent.

Related Conditions & MeSH terms

• Transfusion-associated Circulatory Overload

Intervention

Drug:
• Furosemide
A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
• Normal Saline
A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.

Locations

Country	Name	City	State
Canada	Canadian Blood Services	Toronto	Ontario
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	University Health Network	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre	Canadian Blood Services, University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

References & Publications (4)

AABB (2015) AABB Association Bulletin #15-02: Transfusion Associated Circulatory Overload (12/28/15). Vol. 2016,

Alam A, Lin Y, Lima A, Hansen M, Callum JL. The prevention of transfusion-associated circulatory overload. Transfus Med Rev. 2013 Apr;27(2):105-12. doi: 10.1016/j.tmrv.2013.02.001. Epub 2013 Mar 1. Review. — View Citation

Lieberman L, Maskens C, Cserti-Gazdewich C, Hansen M, Lin Y, Pendergrast J, Yi QL, Callum J. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. Transfus Med Rev. 2013 Oct;27(4):206-12. doi: 10.1016/j.tmrv.2013.07.002. Epub 2013 Sep 26. Review. — View Citation

Sarai M, Tejani AM. Loop diuretics for patients receiving blood transfusions. Cochrane Database Syst Rev. 2015 Feb 16;(2):CD010138. doi: 10.1002/14651858.CD010138.pub2. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients enrolled		2 months period
Secondary	Proportion of patients screened meeting eligibility criteria		2 months
Secondary	Proportion of eligible patients consenting to participate		2 months
Secondary	Proportion of patient receiving the allocated treatment		2 months
Secondary	Proportion of treated patients completing follow-up assessment		2 months
Secondary	Proportion of patient in which blinding was maintained throughout study		2 months
Secondary	Vital Signs	Change in vital signs immediately post-transfusion and at 6 hours post-transfusion	Baseline and 6 hours post transfusion
Secondary	Positive end-expiratory pressure	For patients on mechanical ventilation pre-transfusion, change in positive end-expiratory pressure	Baseline and 6 hours post transfusion
Secondary	Inspiratory oxygen	change in fraction of inspiratory oxygen at 6 hours post-transfusion	Baseline and 6 hours post transfusion
Secondary	Incidence of TACO within 6 hours from completion of transfusion		within 6 hours
Secondary	Severity of TACO-graded as per the Public Health Agency of Canada's Transfusion Transmitted Injuries Surveillance System		within 6 hours
Secondary	Validation of TACO as per criteria adopted from the US Center for Disease Control		within 6 hours
Secondary	Change in plasma brain natriuretic peptide(BNP)		Baseline and Day 1
Secondary	Net fluid balance at 24 hours from start of transfusion- all intravenously-administered fluids (including the transfused blood product and the study intervention)		Within 24 hours
Secondary	Proportion of patients developing hyponatremia or hypokalemia by Day 1		By Day 1
Secondary	Proportion of patients developing hypotension		Within 24 hours
Secondary	Proportion of patients developing acute kidney injury		Within 24 hours
Secondary	Need for increased supplemental oxygen is defined as any increase in oxygen flow = 1 L/hr or (fraction of inspired oxygen)FiO2 = 5% of 1 hour duration or longer, prompted by either patient symptoms or a fall in oxygen saturation(SpO2) = 5%		Within 24 hours
Secondary	Need for inotropic support is defined as the initiation of a continuous infusion of dopamine, dobutamine, epinephrine, or norepinephrine		Within 24 hours
Secondary	Need for additional diuretic or vasodilatory therapy is defined by the prescription of non-study furosemide, hydrochlorothiazide, metolazone, or either transdermal or intravenous nitroglycerin		Within 24 hours
Secondary	Occurrence of acute coronary syndrome or new arrhythmia		within 7 days
Secondary	Mortality during hospital stay		Upto 30 days
Secondary	Length of hospital stay		From date of admission until the date discharge from an acute care hospital or date of death from any cause, whichever came first, assessed up to 30 days.